Please login to be able to save your searches and receive alerts for new content matching your search criteria.
The purpose of this study is to explore the psychological efficacy of Xinwei Decoction, a traditional Chinese herbal medicine, to treat functional dyspepsia (FD) accompanied with depression and anxiety. Seventy-three subjects, divided into three groups, had been given herbal medicine (Xinwei Decoction), prokinetic agent (Domperidone) and placebo, respectively for 8 weeks. Before and after treatment, all subjects were examined with FD symptom scale, Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA). As a result, the total scores of the three groups in FD symptom scale, HAMD and HAMA after treatment decreased in different levels, with the decrease in the herbal group more significant than the other two groups (p<0.01), indicating the efficacy of the herbal medicine. The total effective rates of the herbal, Domperidone and placebo groups were 90%, 67% and 31%, respectively, which indicated significant effect differences between Xinwei Decoction and Domperidone (p<0.05) and between Xinwei Decoction and placebo (p<0.01), showing that the efficacy of herbal therapy was superior to that of the other two therapies. Furthermore, there was no one in the Domperidone and placebo groups being cured of depression and anxiety, while the curing rate in the herbal group was about 70%, indicating the efficacy of herbal medicine in comparison to that of Domperidone and placebo for anti-depression and anti-anxiety. The result demonstrated that Xinwei Decoction could not only alleviate FD symptoms but also relieve depression and anxiety.
Objective: To observe efficacy of pyonex in the treatment of functional dyspepsia (FD) with mild to moderate depression.
Methods: 64 FD patients with mild to moderate depression were randomly divided into control group (N=32) and test group (N=32). The test group was given mosapride combined with pyonex, acupuncture at Neiguan, Shenmen, Zusanli and Taichong, and the control group was given mosapride combined with sertraline. The course of treatment was 4 weeks in both groups. The changes of LDQ and HAMD scores were compared between the two groups before and after treatment, and the safety and efficacy were evaluated.
Results: ① LDQ scores: The total efficacy of the test group was 87.5%, and that of the control group was 81.3% after treatment. The curative effect of the test group was similar to that of the control group (P>0.05). The total LDQ scores and single symptom scores of the test group were significantly better than those of the control group (P<0.05). ② HAMD scores: The both groups were significantly improved as compared with those before treatment (P<0.05). ③ Safety evaluation: There were no obvious adverse reactions in the two groups during the treatment.
Conclusions: Pyonex combined with mosapride can be safe and may improve the clinical symptoms of dyspepsia and depression.